2, Apr-Jun
ARP Rheumatology, Vol 2, nº2 2023
2023
Editorial
The three W’s of type I interferons in rheumatic and musculoskeletal diseases: why, what and who?
Page numbers: 94-96
Original articles
In a community-based setting spondyloarthritis patients report higher levels of physical disability than chronic low back pain patients - results from EpiReuma.pt
Page numbers: 97-110
Severe infections in Portuguese patients with rheumatoid arthritis under biologic treatment – a multicenter, nationwide study (SIPPRA-B Study)
Page numbers: 111-119
The impact of antinuclear antibodies seroconversion induced by anti-tumor necrosis factor α agents on the clinical outcomes in rheumatic patients
Page numbers: 120-131
Effectiveness of biosimilar infliximab CT-P13 compared to originator infliximab in biological-naïve patients with rheumatoid arthritis and axial spondyloarthritis: data from the Portuguese Register
Page numbers: 132-140
Predictive factors of fragility fractures and associated mortality: assessment of patients observed at emergency department
Page numbers: 141-147
Cumulative dose and length of methotrexate treatment were not shown to be predictors of hepatic fibrosis by elastography - a monocentric cohort study
Page numbers: 148-154
Reviews
IgG4-related disease and isolated retroperitoneal fibrosis: A narrative review
Page numbers: 155-157
Case-based Review
Eosinophilic Granulomatosis with Polyangiitis – description of a pediatric patient with severe disease
Page numbers: 160-165
Hypokalemic paralysis due to renal tubular acidosis: uncommon initial manifestation of primary Sjögren´s syndrome
Page numbers: 166-169
Images in Rheumatology
Vasculitis in cocaine users - not all that glows is gold
Page numbers: 170-172
Letters to the Editor
ANCA-associated vasculitis after Pfizer-BioNTech COVID-19 vaccination: two case reports
Page numbers: 173-174
Pyogenic extensor tenosynovitis of the ankle with associated synovial cyst caused by Streptococcus pneumoniae - a case report
Page numbers: 175-176
Correspondence on: Perioperative management of disease-modifying antirheumatic drugs and other immunomodulators
Page numbers: 177-178